- Home
- ADCT vs AMRN Comparison
ADCT vs AMRN Comparison
Compare ADCT & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- AMRN
- Stock Information
- Founded
- ADCT 2011
- AMRN 1989
- Country
- ADCT Switzerland
- AMRN Ireland
- Employees
- ADCT N/A
- AMRN N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ADCT Health Care
- AMRN Health Care
- Exchange
- ADCT Nasdaq
- AMRN Nasdaq
- Market Cap
- ADCT 285.2M
- AMRN 236.4M
- IPO Year
- ADCT 2020
- AMRN 1993
- Fundamental
- Price
- ADCT $1.98
- AMRN $0.52
- Analyst Decision
- ADCT Strong Buy
- AMRN Buy
- Analyst Count
- ADCT 5
- AMRN 1
- Target Price
- ADCT $7.33
- AMRN N/A
- AVG Volume (30 Days)
- ADCT 417.8K
- AMRN 1.3M
- Earning Date
- ADCT 11-07-2024
- AMRN 10-30-2024
- Dividend Yield
- ADCT N/A
- AMRN N/A
- EPS Growth
- ADCT N/A
- AMRN N/A
- EPS
- ADCT N/A
- AMRN N/A
- Revenue
- ADCT $70,717,000.00
- AMRN $241,021,000.00
- Revenue This Year
- ADCT $6.66
- AMRN N/A
- Revenue Next Year
- ADCT $16.38
- AMRN N/A
- P/E Ratio
- ADCT N/A
- AMRN N/A
- Revenue Growth
- ADCT N/A
- AMRN N/A
- 52 Week Low
- ADCT $0.69
- AMRN $0.46
- 52 Week High
- ADCT $6.04
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- ADCT 25.90
- AMRN 43.68
- Support Level
- ADCT $1.89
- AMRN $0.54
- Resistance Level
- ADCT $3.06
- AMRN $0.52
- Average True Range (ATR)
- ADCT 0.23
- AMRN 0.03
- MACD
- ADCT -0.11
- AMRN -0.01
- Stochastic Oscillator
- ADCT 8.83
- AMRN 36.06
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.